2025-10-17 - Analysis Report
Okay, let's break down the analysis of Eli Lilly and Co (LLY) based on the provided data.

**Report**

**1. Performance vs. S&P 500 (VOO)**

*   **Ticker:** LLY
*   **Company Description:** Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products.
*   **LLY Cumulative Return:** 211.75%
*   **VOO Cumulative Return:** 96.43%
*   **Spread (LLY - VOO):**
    *   Current: 120.5
    *   Max: 248.5
    *   Min: -33.6
    *   Relative Spread: 54.6

**Analysis:** LLY has significantly outperformed the S&P 500 (VOO) over the period. The current spread of 120.5 indicates substantial outperformance. A relative spread of 54.6 suggests LLY's outperformance is near the median of its historical range compared to VOO.

**Alpha, Beta Analysis**

| Year       | CAGR    | MDD     | Alpha    | Beta  | Cap(B)  |
|------------|---------|---------|----------|-------|---------|
| 2015-2017  | 11.0%   | 76.1%   | -17.0%   | -0.0  | 76.4    |
| 2016-2018  | 39.0%   | 68.9%   | 24.0%    | -0.0  | 104.6   |
| 2017-2019  | 41.0%   | 68.9%   | 19.0%    | 0.4   | 118.8   |
| 2018-2020  | 34.0%   | 79.8%   | 10.0%    | 0.4   | 152.7   |
| 2019-2021  | 53.0%   | 79.8%   | 7.0%     | 0.5   | 249.8   |
| 2020-2022  | 64.0%   | 79.8%   | 65.0%    | 0.4   | 330.8   |
| 2021-2023  | 125.0%  | 78.9%   | 124.0%   | 0.2   | 527.1   |
| 2022-2024  | 134.0%  | 81.2%   | 113.0%   | 0.2   | 698.0   |
| 2023-2025  | 103.0%  | 83.5%   | 42.0%    | 0.2   | 734.5   |

**Analysis:**

*   **CAGR:** The Compounded Annual Growth Rate shows strong growth, particularly in recent years (2021-2025).
*   **MDD:** The Maximum Drawdown is relatively high, indicating significant volatility.
*   **Alpha:**  Alpha is generally positive and has been exceptionally high recently. This signifies LLY's ability to generate returns independent of the market.
*   **Beta:** Beta is low, indicating LLY's price is not as sensitive to market movements.
*   **Cap(B):**  Market capitalization has grown substantially, demonstrating the company's increasing size and influence.

**2. Recent Price Action**

*   **Current Price:** 812.35
*   **Last Market Data:** Price: 819.38, Previous Close: 826.57, Change: -0.87
*   **5-day Moving Average:** 829.12
*   **20-day Moving Average:** 788.22
*   **60-day Moving Average:** 750.50

**Analysis:** The price is currently below the 5-day moving average but above the 20 and 60-day moving averages. The slight decrease in the last market data may indicate a small correction or consolidation.

**3. Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment)
*   **RSI:** 67.13 (Approaching overbought territory)
*   **PPO:** 0.2099
*   **Hybrid Signal:** Cash 0%, Buy 100% of cash (1 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-10-01)
*   **Delta_Previous_Relative_Divergence:** 1.8 (+) Short-term Increase
*   **Expected Return:** 113.0% (Long-term, vs. S&P 500)

**Analysis:**

*   The MRI suggests a medium investment recommendation.
*   The RSI indicates the stock is approaching overbought conditions, which might signal a potential pullback.
*   The PPO indicates there is short term momentum.
*   The Hybrid signal recommends a buy.
*   The positive change in relative divergence suggests short-term upward momentum.
*   The high expected return suggests substantial potential outperformance over the S&P 500 in the long term.
*   The recent market data of {'price': 819.38, 'previousClose': 826.57, 'change': -0.87} is a slight decrease, but not significant enough to indicate a major issue or reversal.

**4. Recent News & Significant Events**

*   **Johnson & Johnson's Potential Challenge:** Johnson & Johnson is positioning itself to compete with Eli Lilly.
*   **Valuation Update:** Eli Lilly's valuation is being re-evaluated following positive Phase 3 results for Orforglipron.
*   **Oral GLP-1 Pill Success:** LLY's oral GLP-1 pill achieved positive results in diabetes trials.
*   **NVO, OMER Deal:** Novo Nordisk (NVO) is expanding its rare disease portfolio, a peripheral but relevant development in the pharmaceutical landscape.
*   **Earnings Announcement:** Lilly has confirmed the date for its Q3 2025 earnings announcement.
*   **Growth Stock Recommendation:** LLY is highlighted as a pharmaceutical growth stock to hold for the long term.

**Analysis:** The news is overwhelmingly positive, focusing on the success of LLY's oral GLP-1 pill and its potential impact on the company's valuation. The mention of Johnson & Johnson's challenge should be monitored.

**4-2. Analyst Opinions**

*   **Consensus:** Buy
*   **Mean Rating:** 1.79 (~Buy)
*   **Opinions:** 27
*   **Target Price (avg/high/low):** 891.00 / 1190.00 / 650.00

**Analysis:** Analyst consensus is strongly bullish, with a buy rating and a mean target price significantly above the current price.

**5. Recent Earnings Analysis**

| Date       | EPS  | Revenue      |
|------------|------|--------------|
| 2025-08-07 | 6.3  | 15.56 B$     |
| 2025-05-01 | 3.07 | 12.73 B$     |
| 2024-10-30 | 1.08 | 11.44 B$     |
| 2024-08-08 | 3.29 | 11.30 B$     |
| 2025-08-07 | 3.29 | 11.30 B$     |

**Analysis:** The most recent earnings data (2025-08-07) shows a significant increase in both EPS and Revenue, indicating strong financial performance.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-06-30 | $15.56B   | 84.27%        |
| 2025-03-31 | $12.73B   | 82.53%        |
| 2024-12-31 | $13.53B   | 82.24%        |
| 2024-09-30 | $11.44B   | 81.02%        |
| 2024-06-30 | $11.30B   | 80.80%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE      |
|------------|-----------|----------|
| 2025-06-30 | $18.27B   | 30.98%   |
| 2025-03-31 | $15.76B   | 17.50%   |
| 2024-12-31 | $14.19B   | 31.07%   |
| 2024-09-30 | $14.24B   | 6.81%    |
| 2024-06-30 | $13.56B   | 21.88%   |

**Analysis:**

*   **Revenue and Profitability:** Revenue and profit margins have consistently increased, showcasing strong financial growth and efficiency.
*   **Capital and Profitability:** Equity has increased steadily, and ROE fluctuates but remains generally strong, indicating efficient use of shareholder equity.

**7. Overall Summary**

Eli Lilly and Co (LLY) presents a compelling investment case based on the provided data:

*   **Strong Performance:** LLY has significantly outperformed the S&P 500, driven by strong growth and high alpha.
*   **Positive Outlook:** Recent news highlights the success of its oral GLP-1 pill and positive analyst sentiment.
*   **Solid Financials:** The company demonstrates robust revenue growth, high profit margins, and efficient use of equity.
*   **Potential Risks:** The RSI indicates the stock might be approaching overbought conditions, and competition from Johnson & Johnson should be monitored. High MDD indicate high volatility.
*   **Recommendation:** Given the overall positive outlook and strong financial performance, LLY appears to be a promising investment, particularly for long-term growth.
